Clinical Trials Brief | April 13, 2026
This week's five signals cover a major proposed cut to NIH funding, a broader FDA shift toward more flexible evidence standards, EMA's tailored biosimilar evidence model, a more practical read on how real-world data is actually being used in trials, and a reported Lilly-Insilico deal that keeps AI drug discovery firmly on the strategic agenda.
The NIH budget fight is becoming a clinical-research infrastructure story, not just a politics story
What changed
Applied Clinical Trials reported that the FY2027 budget request would reduce NIH funding to roughly $41 billion and eliminate several NIH components, while ASCO warned that broad cuts could slow research progress.
Why it matters
NIH funding shapes investigator capacity, translational momentum, and the broader research environment that future trials depend on, even when budget proposals are later revised by Congress.
Takeaway
Budget proposals do not equal enacted reality, but they can still change planning, confidence, and research-system behavior well before final appropriations are set.
Sources
This item is grounded in Applied Clinical Trials' April 6, 2026 reporting, the NCCIH FY2027 Congressional Justification page, and ASCO's public response.
FDA's 2026 moves are starting to look like one coherent evidence-policy shift
What changed
Applied Clinical Trials summarized four early-2026 FDA actions covering single-trial approval logic, individualized ultra-rare disease therapies, new approach methodologies, and Bayesian methods in clinical trials.
Why it matters
The combined signal affects nonclinical planning, adaptive trial design, rare-disease development, and how sponsors think about fit-for-purpose evidence rather than default evidence volume.
Takeaway
The evidentiary bar is not obviously lower. It is becoming more selective, more design-sensitive, and more dependent on stronger regulatory strategy.
Sources
This item is grounded in Applied Clinical Trials' March 23, 2026 FDA synthesis plus official FDA NAM and Bayesian guidance materials.
EMA is still signaling that biosimilar evidence packages may get leaner
What changed
EMA said CHMP adopted a reflection paper intended to reduce the amount of clinical data required for certain biosimilar medicines in the EU.
Why it matters
This remains one of the clearest recent EU signs that regulators are reconsidering how much traditional clinical work is truly decision-relevant.
Takeaway
The better reading is not that evidence matters less, but that regulators may increasingly judge evidence burden by value rather than tradition.
Sources
This item is grounded in EMA's CHMP meeting highlights for March 23-26, 2026.
Real-world data is moving from buzzword to trial-design tool, but unevenly
What changed
Applied Clinical Trials described how real-world data is increasingly being used to optimize eligibility criteria, reduce recruitment burden, support external controls, and inform evidence planning in selected settings.
Why it matters
The practical value of RWD is not as a buzzword, but as a design and evidence tool that can improve feasibility and strategy when data quality, integration, and internal alignment are good enough.
Takeaway
RWD becomes useful when teams treat it as an operational design tool, not as a shortcut around weak trial planning.
Sources
This item is grounded in Applied Clinical Trials' April 3, 2026 feature on real-world data and evidence in clinical trials.
Lilly's reported Insilico expansion suggests big pharma still sees real option value in AI drug discovery
What changed
Secondary-source reporting said Eli Lilly was expanding its relationship with Insilico Medicine in a deal reportedly worth up to $2.75 billion.
Why it matters
This points to where AI still attracts serious strategic capital in pharma: early pipeline creation, target discovery, and molecule-level option building rather than generic AI hype.
Takeaway
The near-term AI story still looks like calculated portfolio optionality, with large companies betting that model-driven discovery can improve odds before the most expensive stages of development.
Sources
This item is grounded in secondary-source reporting from late March 2026 rather than a directly confirmed Lilly or Insilico press release.